Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 760 of 6351
-
New drug combo aims to fight tough kidney cancers
Disease control Recruiting nowBackground: Kidney cancer is the 12th leading cause of cancer-related death in the United States. Some kidney tumors do not respond well to current treatments. Better treatments are needed. Objective: To test a pair of drugs (sasanlimab and palbociclib) in people with kidney c…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Could a Two-Drug combo supercharge weight loss?
Disease control CompletedThe main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits.
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Peer power: could support groups boost HIV prevention in transgender men?
Prevention CompletedTransgender masculine and gender diverse people who have sex with men (TMSM) have an increased risk of human immunodeficiency virus (HIV) and face unique barriers engaging in prevention services. Digitally delivered support interventions addressing HIV prevention barriers deliver…
Sponsor: Fenway Community Health • Aim: Prevention
Last updated Aug 26, 2026 00:00 UTC
-
New shot could tame tough eczema Flare-Ups
Disease control OngoingThe main purpose of this study is to evaluate the efficacy and safety of lebrikizumab with/without Topical Corticosteroid Treatment in Participants with Moderate-to-Severe Atopic Dermatitis. The study will last approximately 62 weeks.
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Brain wave markers may reveal who benefits from mindfulness for migraine
Symptom relief Recruiting nowRecent studies suggest that Mindfulness may be an effective treatment for migraine, reducing the frequency of attacks, depression, anxiety and improving quality of life. However, the pathophysiological mechanisms underlying the effectiveness are not yet fully known. The identific…
Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
New hope for Alzheimer's psychosis: ACP-204 safety trial expands
Symptom relief By invitation onlyThis 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.
Phase 3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Can mindfulness mend minds after ACL surgery?
Symptom relief Recruiting nowAnterior cruciate ligament (ACL) reconstruction surgery is a common procedure performed by orthopedic surgeons. Postoperatively, patients often experience pain, muscle tension, and concerns about their ability to return to sports. These factors influence the recovery and return t…
Sponsor: Chang Gung Memorial Hospital • Aim: Symptom relief
Last updated Aug 02, 2026 00:00 UTC
-
Can a collagen patch make torn shoulder tendons heal stronger?
Disease control Recruiting nowRotator cuff refers to a set of 4 shoulder tendons. These tendons are the sub-scapularis, supra-spinatus, infra-spinatus and teres minor. Rotator cuff tear corresponds to total or partial tendon disinsertion at the greater tuberosity level or a few centimeters in upstream. Rotat…
Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New hope for recurrent prostate cancer: drug combo aims to control PSA without hormone therapy
Disease control Recruiting nowBackground: Prostate cancer may return after treatment in 30,000 to 50,000 people each year. There is no clear best way to treat these people. Better treatments are needed. Objective: To test a study drug (enzalutamide), both alone and combined with a second drug (PDS01ADC), i…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Cord blood cells engineered to fight Hard-to-Treat blood cancers
Disease control Recruiting nowTo determine the safety, efficacy and optimal cell dose of CAR 5/IL15-transduced CB-NK cells in patients with relapsed/refractory T-cell malignances, mantle cell lymphoma, and chronic lymphocytic leukemia. The efficacy and optimal dose will be identified for individual diseases.
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New combo aims to control CLL in just one year
Disease control Recruiting nowThis study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).
Phase 2 • Sponsor: Inhye Ahn • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug cocktail aims to fight head and neck cancer
Disease control Recruiting nowThe purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carboplatin in participants with recurrent/metast…
Phase 1/2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Heated milk ladder could speed up allergy tolerance in kids
Disease control Recruiting nowThis interventional study aims to validate an early heated protein introduction protocol in cow's milk allergic children who already developed tolerance towards extensively heated cow's milk, in order to speed up the development of complete cow's milk tolerance. Natural complete …
Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New combo targets tough lung cancer with promising drug
Disease control OngoingThe purpose of this study is to measure efficacy and safety of osimertinib as induction therapy prior to curative intent CRT and maintenance osimertinib in adult patients with Stage III, unresectable NSCLC with common EGFR mutations (exon 19 deletion or L858R).
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Gene therapy hope for SMA kids: early trial launches
Disease control OngoingThis study is a single-center, open-label, single-arm, non-randomized, single-dose, dose-escalation investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, and preliminary efficacy of NKG001 Injection administered via different dosing regimens (intraveno…
Sponsor: Nikegen Pharmaceutical (Hangzhou) Company Limited • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Engineered immune cells take on relapsed blood cancers
Disease control Recruiting now1. Study Title: A Study on the Efficacy and safety of Autocrine p40-Expressing CD19-Targeted Chimeric Antigen Receptor T Cells (CD19-CAR.p40-T) in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies 2. Study Objectives: 2.1.1 Primary Objective To eval…
Phase 1/2 • Sponsor: Shenzhen University General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New vaccine targets 24 pneumococcal strains in major trial
Vaccine CompletedA phase II clinical trial of a 24-valent pneumococcal conjugate vaccine (PCV24) developed by Shanghai Reinovax Biologics Co., LTD will be conducted in Chinese adults aged 18 years and older. The study's objective is to evaluate the safety and immunogenicity of PCV24. The trial is…
Phase 2 • Sponsor: Reinovax Biologics Co., LTD • Aim: Vaccine
Last updated Aug 19, 2026 00:00 UTC
-
AI takes the guesswork out of insulin dosing for hospital patients
Disease control CompletedOur study was a single-blind, randomised, controlled, multicentre study. The study was planned to enrol 142 patients with T2DM admitted to general wards who required subcutaneous insulin therapy. Participants were randomly divided into two groups in the ratio of 1:1, one group wi…
Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug cocktail targets tough colorectal cancer
Disease control OngoingThe aim of this study is to evaluate the efficacy and safety of Tislelizumab with Fruquintinib, Metronidazole treatment in MSS/MSI-L advanced colorectal cancer patients with high abundance of Fusobacterium nucleatum in a single arm Phase II clinical.
Phase 2 • Sponsor: Jing-yuan Fang, MD, Ph. D • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Weekly insulin shot could replace daily pokes for diabetes
Disease control CompletedThis study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes. Participants will either get insulin icodec or insulin glargine. Which treatment pa…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC